Comparing ARomatase Inhibition when given with or without SaracaTinib as an Advanced breast CAncer Therapy (ARISTACAT): a randomised phase II study of aromatase inhibition with or without the src-inhibitor AZD0530 in post-menopausal women with advanced breast cancer

Trial Profile

Comparing ARomatase Inhibition when given with or without SaracaTinib as an Advanced breast CAncer Therapy (ARISTACAT): a randomised phase II study of aromatase inhibition with or without the src-inhibitor AZD0530 in post-menopausal women with advanced breast cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Saracatinib (Primary) ; Anastrozole; Exemestane
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms ARISTACAT
  • Most Recent Events

    • 03 Apr 2017 Status changed from recruiting to completed.
    • 17 Apr 2015 Accrual to date is 93% according to United Kingdom Clinical Research Network record.
    • 08 Feb 2015 Accrual to date is 92% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top